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Table 1
Gene Expression Proﬁle
RESISTANT VS NON-RESISTANT AML
Gene DD Ct (mean, SEM) 95% CI P-value Relative
fold change
JAK2 -5.38 (0.94) -7.67 -3.08 0.0012 41.52
S100A8 -7.16 (2.66) -14.01 -0.32 0.0432 143.27
S100A9 -8.31 (2.75) -15.04 -1.59 0.0233 318.37
c-myc -2.78 (0.59) -4.24 -1.33 0.0034 6.89
JAK1 -4.63 (1.98) -9.48 0.21 0.0579 24.83
JAK3 -5.90 (2.17) -12.81 1.01 0.0726 59.77
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Background: Ex-vivo expansion of CBT-cells using CD3/
CD28 co-stimulatory beads, IL-2 + IL-7 & subsequent priming
against leukemia cell lines using IL-15 generated speciﬁc
CTLs. [1, 2] Using similar immune-stimulatory culture con-
ditions, we generated auto PB-derived CTLs from AML pa-
tients in 5 of 8 samples. [Abstract #5836] The aim of present
study was to ﬁnd source of disparity between “resistant”
(n¼3) & non-resistant AML (n¼5).
Hypothesis: We hypothesized (a) in contrast to AML cells
that are susceptible to cytotoxicity by auto CTLs (n¼5), the
“resistant” AML cells (n¼3), would possess features similar to
myeloid-derived suppressor cells (MDSCs).
Methods: AML blasts were puriﬁed from PBMCs of AML
patients admitted with blast crisis (n¼8). AML-speciﬁc auto
CTLs were generated using immune-stimulatory culture
conditions as described. [Abstract #5836] RNA puriﬁcation &
RT-qPCR from blasts was done using Trizol reagent (Life
Technologies) & Power SYBR Green master mix (Applied
Biosystems) with StepOne Plus system (Life Technologies) as
suggested by manufacturers. Genes with deﬁned role in
MDSC generation [2] were selected for analysis. Primers
were designed using NCBI primer blast. [3] GAPDH was used
as house-keeping gene. Student t-test was used to compare
the groups.
Results: Resistant blasts had signiﬁcant up-regulation
of JAK-2, S100A8, S100A9 and c-myc compared to the
susceptible blasts. [Table 1] Although JAK-1 and JAK-3Figure 1. Signaling pathways involved in the expansion of mDSCs [2] (rwere up-regulated notably, statistical signiﬁcance was
not met.
Discussion: JAK-2 signaling pathway is critical for MDSC
generation and survival, which induces c-myc expression,
while S100A8 & S100A9 potentiate the suppressive effects of
MDSC. [Figure 1] [2] Many solid tumors assume MDSC-like
phenotype, [2] but this is rarely reported in hematological
malignancies. [3, 4] Our ﬁndings mandate further validation.
If replicated, therapeutic roles of JAK and S100 pathway in-
hibitors could be explored.
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Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205 S193Pediatric patients with refractory/relapsed acute myeloid
leukemia (AML) have only one treatment option: hemato-
poietic cell transplantation (HCT). Using cord blood (CB)-
derived stem cells, instead of cells from bone marrow cells or
peripheral blood, results in less relapses (increased anti-
tumor reactivity) and less graft-versus-host disease
(increased safety). Although this treatment is potentially
curative, still more than half of the children die from re-
lapses. We therefore aim to develop additional powerful and
safe CB-derived immunotherapies for pediatric AML. First,
we developed a dendritic cell (DC) vaccine, derived from the
CB stem cells with the goal to stimulate the anti-tumor
reactivity of the newly developing immune system in AML
patients after CB-HCT. CD34+ CB stem cells were expanded
and differentiated into DCs. CBDCs upregulated co-stimula-
tory molecules after maturation and showed enhanced
CCR7-dependent migration towards CCL19 in a trans-well
migrations assay. In addition, CBDCs expressed the tumor
antigen Wilms’ Tumor 1 (WT1) protein after electroporation
with WT1-mRNA. These WT1 expressing CBDCs were not
only able to stimulate T cells in a mixed lymphocyte reaction
but in an antigen-speciﬁc setting as well.
Second, we are testing additional immunotherapies that can
be used combined with CBDC vaccination, i.e. NK cells and
gamma delta T cells. All of which may either enhance the
immune stimulating function of the CBDCs, or can be acti-
vated by CBDCs to directly and/or indirectly target the AML
cells. As such, these addition immunotherapies will further
intensify the anti-tumor reactivity of CB-HCT and not only in
the AML setting but potentially also in several solid tumors.250
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Objectives: Up to one third of patients with acute myeloid
leukemia (AML) relapse following allogeneic hematopoietic
stem cell transplantation (SCT) in morphologic complete
remission (mCR). We hypothesized that that the cytogenetic
pattern of relapse is related to cytogenetic risk group at
diagnosis.
Methods: We analyzed the data from a cohort of patients
(n ¼ 45) with AML and abnormal cytogenetics who relapsed
following SCT in mCR. Cytogenetic abnormalities were
identiﬁed by ﬂuorescence in situ hybridization (FISH) and
metaphase cytogenetics.
Results: All transplants were performed using peripheral
blood stem cells. The mean (standard deviation) age of pa-
tients was 53 (15) years, and 47% were male. AML was
therapy-related in 8 (18%) patients. The most frequent FAB
subtypes were M0/M1/M2 (38%) and M4/M5 (38%). Favor-
able/Intermediate and unfavorable cytogenetic risk disease
was present in 11 (24%) and 34 (76%) patients, respectively.
Persistent cytogenetic abnormalities despite mCR were
present before SCT in 49% of patients. 84% of patients were in
CR1. Conditioning was myeloablative in 49% of patients. The
donor was a matched sibling, matched unrelated donor, or
haploidentical relative in 47%, 51%, and 2% of patients,
respectively. Primary graft failure did not occur in any pa-
tient. 29% and 4% of patients had CMV reactivation anddisease, respectively. Acute and chronic GvHD occurred in
27% and 13% of patients, respectively. The median time to
relapse and overall survival from the time of transplant were
3.5 (interquartile range: 1.7-5.3) and 10 (8.9-11.2) months,
respectively. Three patterns of relapse were identiﬁed: same
clone (n ¼ 23, 51%), subclone (n ¼ 17, 38%), and new clone (n
¼ 5, 11%). The latter two were grouped together during
analysis because both represented clonal evolution. The only
difference in the baseline and transplant characteristics be-
tween patients who relapsed with the same clone versus
those who relapsed with clonal evolution was cytogenetic
risk group. Speciﬁcally, patients with high risk cytogenetics
at diagnosis were more likely to relapse with the same clone
than those with low/intermediate risk cytogenetics (62% vs.
18%, respectively; P ¼ 0.017). There was no difference in
median time to relapse (same clone, 3.2 months vs. clonal
evolution, 3.5 months, P ¼ 0.67) or overall survival (9.4 vs
10.0 months, respectively; P ¼ 0.88) based on the type of
clone at the time of relapse.
Conclusions: In patients with AML and abnormal cytoge-
netics who undergo SCT in mCR, the same clone is respon-
sible for relapse in a signiﬁcantly higher proportion of those
with unfavorable risk cytogenetics at the time of AML diag-
nosis compared to those with favorable/intermediate risk
disease. This may be due to higher rates of minimal residual
disease after SCT in patients with unfavorable risk disease.
Next-generation sequencing may add ﬁner resolution to our
ﬁndings.251
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Background: CMML is a clonal hematopoietic stem cell
disorder with myelodysplastic and myeloproliferative over-
lap features and a high tendency to progress to acute leu-
kemia. Although treatment options include supportive care
and use of hypomethylating agents, allogenic hemopoietic
stem cell transplant (allo HCT) remains the only curative
option. We sought to evaluate outcomes in patients with
CMML that underwent allo HCT.
Methods: After IRB approval, consecutive adult patients with
CMML who underwent allo HCT from 1990 to 2014 were
identiﬁed and evaluated. All data were retrospectively
abstracted. Conditioning regimens, GVHD prophylaxis and
transfusions were according to institutional standards.
Results: Thirty-six patients (males 23%) who met WHO
criteria for CMML were included. The median age was 53
years (range, 18 to 66 years) and 20 patients (56%) had
CMML-1, while 16 patients (44%) had CMML-2. Patient dis-
tribution according to Mayo risk category was: 20 high-risk,
9 intermediate-risk and 7 low-risk while distribution ac-
cording to Spanish karyotype was: 9 high-risk, 7 interme-
diate-risk and 20 low-risk.
Twenty-two received myeloablative conditioning (me-
dian age: 49 years) and 14 received reduced-intensity con-
ditioning (median age: 59 years). At the time of transplant,
20 patients had received induction chemotherapy, 6 had
received hypomethylating agents and 10 were managed by
supportive care. Twenty-six patients (72%) experienced
acute graft-versus-host disease (GVHD) (15 grade II-IV) and
23 (64%) patients experienced chronic GVHD (11 severe).
Post-transplant complete remission was achieved in 25
